The activation of factor XI initiates the intrinsic coagulation pathway. Until recently it was believed that the main activator of factor XI is factor Xlla in conjunction with the cofactor high molecular weight kininogen on a negatively charged surface. Two recent reports have presented evidence that in a purified system factor XI is activatable by thrombin together with the soluble polyanion dextran sulfate. To assess the physiological relevance of these findings we studied the activation of factor XI in normal and factor XII-deficient plasma. We used either kaolin/cephalin or dextran sulfate as a surface for the intrinsic coagulation pathway, tissue factor to generate thrombin via the extrinsic pathway, or the addition of a-thrombin directly. '*'I-factor XI, added to factor XI-deficient plasma at physiologic concentrations (35 nmol/L), is rapidly cleaved on incubation with kaolin. The kinetics appear to be exponential with half the maximum cleavage at 5 minutes. Similar kinetics of ONTACT ACTIVATION of blood plasma is initiated C when the plasma proteins factor XII, prekallikrein, and high molecular weight kininogen interact with negatively charged solids such as glass' or kaolin,2 colloids like ellagic acid/metal ion c~mplexes,~ or soluble polyanions such as dextran sulfate or h e~a r i n .~ Consequences of this process include bradykinin generation and the initiation of the intrinsic coagulation pathway through activation of factor XI by activated factor XI1 (factor XIIa). However, patients deficient in either factor XII, prekallikrein, or high molecular weight kininogen show no signs of a bleeding disorder, whereas patients with factor XI deficiency, a disease most common among Ashkenazi Jews, show a mild to moderate bleeding tendency. Although this bleeding tendency is not correlated with the level of functional factor XI, it is believed that an alternative pathway of factor XI activation exists, independent of the contact activation system. A platelet factor XI, immunologically and functional similar but not identical to plasma factor XI, has been de~cribed.~ Another piece of evidence for the involvement of platelets is the notion that concomitant aspirin treatment seems to increase the incidence of bleeding in factor XI deficiency! Two recent publication^'.^ .00/0 factor XI cleavage are seen when 40 nmol/L factor Xlla (equal to 10% of factor XI1 activation) is added to factor XII-deficient plasma if an activating surface is provided.
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The activation of factor XI initiates the intrinsic coagulation pathway. Until recently it was believed that the main activator of factor XI is factor Xlla in conjunction with the cofactor high molecular weight kininogen on a negatively charged surface. Two recent reports have presented evidence that in a purified system factor XI is activatable by thrombin together with the soluble polyanion dextran sulfate. To assess the physiological relevance of these findings we studied the activation of factor XI in normal and factor XII-deficient plasma. We used either kaolin/cephalin or dextran sulfate as a surface for the intrinsic coagulation pathway, tissue factor to generate thrombin via the extrinsic pathway, or the addition of a-thrombin directly. '*'I-factor XI, added to factor XI-deficient plasma at physiologic concentrations (35 nmol/L), is rapidly cleaved on incubation with kaolin. The kinetics appear to be exponential with half the maximum cleavage at 5 minutes. Similar kinetics of ONTACT ACTIVATION of blood plasma is initiated C when the plasma proteins factor XII, prekallikrein, and high molecular weight kininogen interact with negatively charged solids such as glass' or kaolin,2 colloids like ellagic acid/metal ion c~mplexes,~ or soluble polyanions such as dextran sulfate or h e~a r i n .~ Consequences of this process include bradykinin generation and the initiation of the intrinsic coagulation pathway through activation of factor XI by activated factor XI1 (factor XIIa). However, patients deficient in either factor XII, prekallikrein, or high molecular weight kininogen show no signs of a bleeding disorder, whereas patients with factor XI deficiency, a disease most common among Ashkenazi Jews, show a mild to moderate bleeding tendency. Although this bleeding tendency is not correlated with the level of functional factor XI, it is believed that an alternative pathway of factor XI activation exists, independent of the contact activation system. A platelet factor XI, immunologically and functional similar but not identical to plasma factor XI, has been de~cribed.~ Another piece of evidence for the involvement of platelets is the notion that concomitant aspirin treatment seems to increase the incidence of bleeding in factor XI deficiency! Two recent publication^'.^ factor XI cleavage are seen when 40 nmol/L factor Xlla (equal to 10% of factor XI1 activation) is added to factor XII-deficient plasma if an activating surface is provided.
Tissue factor (1 :500) added to plasma did not induce cleavage of factor XI during a 90-minute incubation, although fibrin formation within 30 seconds indicated that thrombin was generated via the extrinsic pathway. Adding 1 pmol/ L a-thrombin (equivalent to 50% prothrombin activation) directly to factor XI1 deficient or normal plasma (with or without kaolin/cephalin/Ca2 + or dextran sulfate) led to instantaneous fibrinogen cleavage, but again no cleavage of factor XI was observable. We conclude that in plasma surroundings factor XI is not activated by thrombin, and that proposals of thrombin initiation of the intrinsic coagulation cascade are not supportable. describe the activation of purified factor XI by thrombin or by autoactivation, both in the presence of negatively charged surfaces. To assess the relevance of these findings in vivo we examined the effect of thrombin on factor XI in plasma, either added exogenously or endogenously generated via tissue factor.
MATERIALS AND METHODS
Factors XI, XII, and XIla were obtained from Enzyme Research Laboratories Inc (South Bend, IN). The low molecular weight form of activated factor XII, factor XI1 fragment (factor XIIf), was prepared by digestion of factor XI1 by kallikrein as described earlier.9 Human a-thrombin (factor Ila) was a kind gift of Dr Jolyon Jesty (Division of Hematology, SUNY Stony Brook, NY). Tissue factor was prepared from 0.5 g human brain powder (acetone washed, kindly provided by Dr Jesty), dissolved in 10 mL 50 mmol/L TRIS, 100 mmol/L NaCI, pH 7.5, heated for 15 minutes at 45"C, centrifuged (5 minutes, 12,000 rpm), and the supernatant aliquoted and stored at -70°C until use. Tissue factor was used in a final dilution of 1:500 with Ca2+ in a final concentration of 25 mmol/L. The molecular weights used to calculate protein concentrations were: factor XI1 and factor XIIa, 80 Kd; factor XIlf, 32 Kd: factor XI, 143 Kd; a-thrombin, 37 Kd.
Factor XI was radiolabeled with '"1 (ICN, Irvine, CA) using solid phase chloramine T (Iodobeads; Pierce, Rockford IL) to a specific activity of 5.64 X IO5 cpm/pg with a protein concentration of 50 ppl mL as determined by absorption at 280 nm (Alo 13.4). A second preparation of factor XI (purified by polybrene free protocol, kindly provided by Dr Jesty) was radiolabeled with the N-hydroxysuccinimide ester of '2sI-3-(4-hydroxyphenyl)propionic acid (Bolton-Hunter reagent; ICN, Irvine, CA) to a specific activity of 2.29 X IO5 cpm/ pg, 140 pg/mL protein. All experiments were performed with both preparations and gave comparable results.
Factor XI-and factor XII-deficient plasmas were obtained from George King Bio-Medical (Overland Park, KS).
Kaolin/cephalin solution consisted of 20 mg/mL Kaolin (Sigma, St Louis, MO) and a 1:lO dilution of rabbit brain cephalin (Sigma; stock prepared as recommended by manufacturer) in 154 mmol/L NaCl and was added to the different plasmas at 25% vol/vol to initiate contact activation. In the experiments with kaolin alone a 25 mg/ mL stock suspension in 154 mmol/L NaCl was used.
Factor XI-deficient plasma was reconstituted by the addition of 1251-factor XI to give a final concentration of 35 nmol/L. The reconstituted plasma was either mixed with 25% (vol/vol) kaolin/cephalin or 2.5 mg/mL kaolin, incubated at room temperature and at different timepoints aliquots of this suspension were added to boiling reducing sodium dodecyl sulfate (SDS) buffer (final composition: 62.5 mmol/ L TRIS-HCI, 2% SDS, 10% glycerol, 0.001% bromophenol blue, 5% P-mercaptoethanol) and subjected to SDS-polyacrylamide electrophoresis (SDS-PAGE).
To study thrombin action on factor XI, we added a-thrombin (final 400 nmol/L) or tissue factor/Ca2' (final 0.2%/25 mmol/L) to I2%factor XI augmented factor XII-deficient plasma with or without 25% kaolin/cephalin/Ca2+. Under these conditions, a fibrin clot formed rapidly that trapped the kaolin particles; therefore, it was only possible to sample the supernatant, not the kaolin suspension as we did in the previously described procedure. Because we observed a continuous absorption of '251-factor XI to the fibrin-immobilized kaolin over time we modified our procedure. For these experiments we incubated individual aliquots of 12SI-factor XI augmented factor XII-deficient plasma/25% kaolin/cephalin with 1 pmol/L a-thrombin (+Ca2+, final 25 mmol/L) or tissue factor/Ca2+ (final 0.2%/25 mmol/ L, 525% kaolin/cephalin) and added reducing SDS buffer directly to the tube for each timepoint. With this procedure we were able to recover the kaolin-bound 12SI-factor XI, regardless whether the fibrin was crosslinked by factor XI11 (with Ca2+) or not (without Ca").
In experiments with dextran sulfate, the compound was added (final 10 to 200 Fg/mL) to '251-factor XI augmented factor XII-deficient plasma followed by a-thrombin (final 1 pmol/L). Under these conditions almost instantaneous coagulation occurred; therefore, we used the above-described technique of adding reducing SDS buffer directly into the tubes for each timepoint to ensure recovery of 1251-factor XI.
SDS-PAGE was performed on 3-mm 10% polyacrylamide minislab gels using the buffer system of Laemmli'O The gels were fixed in 25% isopropanol, 10% acetic acid for 30 minutes, rinsed in H20, dried under vacuum for 2 hours at 70°C (Gel Dryer 543; Biorad, Richmond, CA) and autoradiographed on preflashed X-OMAT AR film (Kodak, Rochester, NY), with a Kodak regular X-OMATIC intensifying screen. The exposure time was chosen so that the darkest band almost saturated the film. After development the films were scanned at 300 dpi resolution using a Hewlett-Packard ScanJet Plus scanner, interfaced to a Macintosh IIci computer. The resulting TIFF image was analyzed using Image, an image processing and analysis program by Wayne Rasband (National Institutes of Health, Research Services Branch NIMH, Bethesda, MD). The relative intensity of the bands was calculated from the areas under the peaks on plots of optical density vs. migration distance. This procedure gave a linear relationship between cpm loaded on the gel and area under the density curves 
RESULTS
To follow the cleavage of factor XI in plasma without artificially increasing its concentration, we added 1251-factor XI at physiologic concentrations (35 nmol/L) to congenital factor XI-deficient plasma. When this reconstituted plasma was treated with either 1/4 vol kaolin/cephalin or 2.5 mg/mL kaolin alone, the labeled factor XI was rapidly cleaved (Fig  1) . The extent of cleavage approached 90% after 1 hour but 50% cleavage was achieved in only 5 minutes. After a short lag phase of approximately 1 minute the first 15 minutes of this reaction followed exponential kinetics and a semilogarithmic plot of this part of the curve gave a straight line; afterwards the reaction leveled off, but even after 60 minutes of incubation the cleavage of 1251-factor XI continued at a low rate. When Ca2+ (final concentration 25 mmol/L) was added to this substituted plasma at the end of the experiment, clotting occurred within 3 minutes, thus indicating the ability of our 12'I-factor XI preparation to activate factor IX and hence initiate the intrinsic pathway.
The previous experiment demonstrated the initiation of the intrinsic coagulation pathway via contact activation. We next investigated possible activation of factor XI in plasma by thrombin. For these experiments we used factor XII-deficient plasma to obviate factor XIl's contribution to any activation of the intrinsic pathway. We augmented the endogenous factor XI with the same concentration of 1251-factor XI as in the experiments described above. It should be noted that in these conditions the plasma contained equal concentrations of endogenous factor XI and added I2'I-factor XI. As shown below (see Fig 3) we obtained similar rates of cleavage of the 1251-labeled protein to that obtained above where only 1Z51-labeled protein was present, thus indicating that the endogenous factor XI is not a preferred substrate compared with the added labeled factor XI. To expose factor XI to thrombin in a plasma milieu, we either added thrombin directly to plasma or generated thrombin in situ via the extrinsic pathway following the addition of tissue factor. The original investigation^'.^ of thrombin-mediated factor XI activation in a purified system used dextran sulfate as the activating "surface." Accordingly, we also included a surface in these experiments, either kaolin or dextran sulfate.
Initially, a-thrombin at a final concentration of 1 pmol/L was added directly to the '251-factor XI augmented factor XII-deficient plasma. This concentration is equivalent to 50% prothrombin activation (and is approximately a 29-fold molar excess over 1251-factor XI). In these experiments, fibrin clots were formed instantly with or without kaolin/cephalin/Ca2+.
Alternatively, tissue factor ( 1500 dilution) and Ca2+ at a final concentration of 25 mmol/L was added to either factor XI1 or factor XI-deficient plasma augmented with '251-factor XI.
Clotting, and therefore thrombin generation, occurred within 1.5 minutes; if kaolin/cephalin was also present, clotting occurred in less than 30 seconds. With either reagent, as described in Materials and Methods, the kaolin was trapped by the fibrin clot. We observed that 1251-factor XI in the remaining serum was adsorbed to the fibrin-immobilized kaolin, apparently following logarithmic kinetics over the 3 hours studied, with half-maximal adsorption after = 10 minutes. Although no factor XI cleavage was observed, the possibility remained that factor XI adsorbed to the kaolin/fibrin solid phase became cleaved. To avoid this complication, we used individual aliquots for each timepoint and added SDSsample buffer to the tube and boiled the samples before electrophoresis; the bound factor XI was recovered by this procedure. As shown in Fig 1, no cleavage of 1251-factor XI was seen after the addition of either a-thrombin or tissue factor over the time course of this experiment (90 minutes). In the absence of kaolin, 1251-factor XI was not bound to polymerized and/or cross-linked fibrin nor was any cleavage observed.
For To determine ifdextran sulfate induced thrombin mediated cleavage of factor XI in plasma, we added 1 pmol/L thrombin/25 mmol/L Ca2+ to '*-%factor XI augmented factor XIIdeficient plasma in the presence of dextran sulfate concentrations varied over the range of 10 to 200 pg/mL. In these experiments, too, clotting occurred almost instantaneously and we used one tube for each timepoint as described above to ensure that all of the original sample was recovered for the gel. trol in which kaolin was added to plasma containing both factor XI and factor XI1 (lanes 1 through 3) . As we observed in the presence of kaolin, thrombin in the presence of dextran sulfate did not induce factor XI cleavage in the absence of factor XII. Similarly, no cleavage was seen by autoactivation of factor XI in the absence of factor XI1 and thrombin (lane 15). The minor band seen at around 50 Kd M W in some of the lanes appears to be a contaminant of the factor XI prep aration; this band is seen on the densitometric plots to have a higher apparent molecular weight than the heavy chain, is 14) and shows no increase over the time course of the incubation.
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We investigated the dependence of factor XI activation on the contact pathway in greater detail using factor XII-deficient plasma reconstituted with various factor XI1 species. First, factor XII-deficient plasma was augmented with 1251-factor XI in a similar manner to the experiments described above and incubated under the same conditions with 114 vol kaolin/ cephalin or dextran sulfate. No cleavage of 1251-factor XI was observed in the time period studied (3 hours, data not shown), thus implying that factor XI in plasma does not autoactivate on kaolin or dextran sulfate. Reconstituting the factor XI1 to physiologic levels (400 nmol/L) restores the cleavage of 1251-factor XI and produces similar kinetics to that seen in '251-factor XI substituted factor XI-deficient plasma (Fig 3) .
We also used factor XIIa to reconstitute factor XII-deficient plasma instead of factor XI1 zymogen. In the presence of a surface (kaolin), we found that 40 nmol/L factor XIIa, which is equivalent to 10% of normal plasma factor XII, was sufficient to obtain a comparable rate of factor XI cleavage as was seen with 400 nmol/L factor XI1 plus kaolin or 1251-factor XI substituted factor XI-deficient plasma plus kaolin. In the absence of a surface, the addition of 400 nmol/L factor XIIa, equivalent to total activation of factor XII, was able to induce the cleavage of only 25% of the 1251-factor XI and the reaction was prematurely terminated when compared with 40 nmol/L factor XIIa with surface. In contrast to factor XIIa, 40 nmol/L factor XIIa was unable to induce the cleavage of factor XI even in the presence of surface (Fig 3) . DISCUSSION Our results indicate that the generation of factor XIa in plasma is contingent on the presence of factor XI1 and a surface; in the absence of either, factor XI is not cleaved. The addition of a high concentration of preformed a-thrombin to plasma does not result in factor XI cleavage, although this reaction has been described with purified protein^.'.^ The activation of the extrinsic pathway and the consequent activation of endogenous prothrombin also did not cause the cleavage of factor XI. A recent abstract by Scott and Colmanll has confirmed the activation of factor XI by thrombin and its autoactivation on surfaces using purified proteins but also found that addition of purified fibrinogen and/or high molecular weight kininogen to the mixture abrogated the reac-. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From tion. Our results in plasma are consistent with this observation.
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We used kaolin as a suface to initiate the intrinsic coagulation pathway because soluble polyanions such as dextran sulfate do not induce clotting in plasma. Because the autoactivation of purified factor XI and its activation by thrombin were demonstrated using dextran sulfate, we also investigated the effect of dextran sulfate in combination with a-thrombin on factor XI in plasma. Although our purified 1251-factor XI did autoactivate on incubation with dextran sulfate (data not shown), dextran sulfate over a broad concentration range did not induce any detectable factor XI cleavage with thrombin in XII-deficient plasma.
The activation of factor XI is the second of two phases of surface-dependent reactions described during the initiation of the intrinsic coagulation pathway, the first being the reciprocal activation of factor XI1 and prekallikrein in which high molecular weight kininogen acts as c~f a c t o r . '~-'~ We experimentally isolated the activation of factor XI by adding preformed activated species of factor XI1 to factor XII-deficient plasma. Under these conditions, 10% factor XIIa (relative to normal [factor XII]) in the presence of a surface induces cleavage of factor XI at a rate similar to that seen in normal plasma. When preformed factor XIIa is added to plasma in the absence of surface, the resulting generation of factor XIa is quantitatively less than in the presence of kaolin, even with 400 nmol/L factor XIIa (equivalent to complete factor XI1 activation), and the reaction rapidly ceases. One interpretation of this is that in the presence of surface, the binding of factor XIIa to kaolin decreases the rate of inhibition of factor XIIa in plasma and also allows the activation of factor XI to proceed rapidly and to completion.
Factor XIIf is a low molecular weight active form of factor XI1 which comprises the serine protease domain but lacks almost the entire heavy chain, including the surface binding Factor XIIf, added to plasma, is unable to cleave factor XI even in the presence of kaolin/cephalin (Fig 3) . Therefore, the binding of factor XI to the surface alone is not sufficient to induce cleavage. The contrast between factor XIIa, which can cleave in the absence of surface, and factor XIIf, which cannot cleave even in the presence of surface, implies that some interaction of the heavy chain of factor XI1 in addition to surface binding is involved in the cleavage of factor XI. The absence of factor XI cleavage after the addition of factor XIIf also indicates that the potential pathway described by Radcliffe et in which factor VI1 is activated by factor XIIf, does not lead to the activation of factor XI.
The absence of significant bleeding in those patients deficient in factor XII, prekallikrein, or high molecular weight kininogen has long been taken to imply that intrinsic coagulation must be able to proceed without them. This has led to speculation and research aimed at discovering an alternative to contact activation as the initiating event. Thus, the presence of a platelet factor XI-like protein has been seen as indicating the possible existence of a factor XII-independent pathway. The current suggestions of a thrombin feedback to activate factor XI would appear to offer a solution to the enigma posed by the requirement for factor XI, but not factor XII, for normal hemostasis. However, our results show that even high concentrations of thrombin in the presence of a surface do not cause factor XI activation if factor XI1 is absent. Therefore, we must conclude that the description of the intrinsic coagulation pathway being initiated by thrombin activation of factor XI, without a role for factor XII,7*8,20 is premature and in our view incorrect. Because the proteins of the contact system are not only involved in the initiating steps required for the intrinsic coagulation pathway, but also the only proteins requisite for bradykinin generation2' and are involved in an intrinsic fibrinolytic ~a s c a d e ,~~-~~ a deficiency of any of these factors might be protective in terms of a bleeding diathesis. To conclude that none of these proteins play a significant role in normal homeostasis because the patients do not bleed may be naive.
